Close Menu

NEW YORK – The National Institute for Health Research (NIHR) Manchester Biomedical Research Centre in the UK said last week that it has launched a clinical trial for a point-of-care PCR-based pharmacogenetic test to predict hearing loss from antibiotic treatment in newborns.

The test uses a cheek swab and delivers a result in less than 30 minutes. It is designed to detect a genetic variant that is present in 1 in 500 individuals. Individuals carrying the mutation suffer from severe hearing loss or deafness if they are treated with the antibiotic gentamicin.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.